BioMarin Pharmaceutical Inc. Appoints Dr. Robert Plenge to Board

What Happened
BioMarin Pharmaceutical Inc. filed an 8-K reporting that its Board increased from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., as an independent, non‑employee director effective September 10, 2026. Dr. Plenge was also named to the Board’s Science and Technology Committee.

Key Details

• Board size increased from 10 to 11 on September 10, 2026.
• Dr. Plenge received a restricted stock unit (RSU) grant valued at $400,000 under the Company’s 2017 Equity Incentive Plan; the RSUs vest on the date immediately prior to the Company’s next regular annual shareholder meeting (same vesting schedule as other 2026 non-employee director awards).
• He will receive the standard non‑employee director fees and committee retainer fees described in BioMarin’s April 21, 2026 proxy statement.
• The Company intends to enter into its standard director indemnification agreement with Dr. Plenge. The filing states he was not appointed pursuant to any outside arrangement and has no reportable related‑party transactions.

Why It Matters
This is a governance update that adds scientific and technology expertise to BioMarin’s Board through Dr. Plenge and modestly expands the Board. The $400,000 RSU award represents standard director compensation and will result in future issuance of shares when those RSUs vest (a potential, limited dilution effect). For investors, the change signals a reinforcement of R&D oversight (Science & Technology Committee membership) and is a routine board-level appointment rather than an executive leadership change.